Publication: Autoreactive IgE: pathogenic role and therapeutic target in autoimmune diseases
Loading...
Program
KU-Authors
Organization Authors
Co-Authors
Charles, Nicolas
Kortekaas-Krohn, Inge
Scheffel, Joerg
Altrichter, Sabine
Steinert, Carolin
Xiang, Yi-Kui
Gutermuth, Jan
Reber, Laurent L.
Maurer, Marcus
Date
Language
Type
Embargo Status
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Autoimmunity is the break of tolerance to self-antigens that leads to organ-specific or systemic diseases often characterized by the presence of pathogenic autoreactive antibodies (AAb) produced by plasmablast and/or plasma cells. AAb are prevalent in the general population and not systematically associated with clinical symptoms. In contrast, in some individuals, these AAb are pathogenic and drive the development of signs and symptoms of antibody-mediated autoimmune diseases (AbAID). AAb production, isotype profiles, and glycosylations are promoted by pro-inflammatory triggers linked to genetic, environmental, and hormonal parameters. Recent evidence supports a role for pathogenic AAb of the IgE isotype in a number of AbAID. Autoreactive IgE can drive the activation of mast cells, basophils, and other types of Fc & epsilon;RI-bearing cells and may play a role in promoting autoantibody production and other pro-inflammatory pathways. In this review, we discuss the current knowledge on the pathogenicity of autoreactive IgE in AbAID and their status as therapeutic targets. We also highlight unresolved issues including the need for assays that reproducibly quantify IgE AAbs, to validate their diagnostic and prognostic value, and to further study their pathophysiological contributions to AbAID.
Source
Publisher
Wiley
Subject
Citation
item.page.haspartof
Source
Allergy
item.page.ispartofseries
item.page.edition
DOI
10.1111/all.15843
